With the same focus, #SpecializedDiagnostics, Werfen and Omixon are the perfect match. The Omixon team is excited to join Werfen and contribute to #PoweringPatientCare.

Contact us: info@werfen.com | Visit Werfen.com

  • Products
  • About Us
  • Blog
  • Omixon Academy
  • Resources
  • Contact us
  • Search
  • Request HLA Assay
  • Request HLA Software
  • MyOmixon
Want to meet us? Let's meet and have some fun! Omixon hugely enjoy the social aspects of conferences. Say hello at our booth, share a wine or beer at the conference reception or cocktail later at the bar!

ARSHI Regional Workshop, October 30-31, 2019

28/10/2019
ARSHI Regional Workshop will take place in Kuwait City, Kuwait. Read more about the scientific program and register here…

 

Read more

Tagged ARSHI, Conference, event

30 Years Peaceful Revolution, November 14-15, 2019

21/10/2019
We are happy to announce that Omixon is sponsoring the “30 Years Peaceful Revolution: From the Peptide to Treatment” Symposium at Universitätsklinikum Leipzig, Germany. Omixon’s Senior Field Application Scientist, Nina Lauterbach will give a 20-minute presentation on our products. Title of her talk: Analysis of High-resolution HLA Typing by...

 

Read more

Tagged Conference, event, hla, HLA typig, holotype hla, ngs

Omixon to Launch OmniType – Join Our Early Access Program!

21/10/2019
Omixon is gearing up to launch a Multiplex HLA typing product for use on Illumina sequencing platforms. This new product line – OmniType – is expected to be a best-in-class product featuring locus multiplexing and short library preparation. The requirements for its development came both from you in the...

 

Read more

Tagged EAP, earlyaccess, hla, HLA Genotyping, multiplex, newproduct, ngs, Omnitype

ABTO, October 16-19, 2019

02/10/2019
Omixon is happy to announce that we are one of the exhibitors of the upcoming ABTO 2019 conference being held in Campinas, Brazil. Read more of the conference and register here…

 

Read more

Tagged ABTO, Conference, event, transplantation

Interview with Gergely Tölgyesi, Molecular Biologist at Omixon

30/09/2019
The following interview is part of the Omixon interview series that we are conducting with Key Opinion Leaders, Experts and Business Managers at Omixon. This time  Gergely Tölgyesi, Technical Lead of Assay R&D answers questions related to his professional background, history of joining the Omixon team and shares secrets...

 

Read more

Tagged Gergely Tölgyesi, hla, holotype hla, molecular biology, ngs, Omnitype

Post navigation

← Older posts
Newer posts →

Werfen acquires Omixon

NANOTYPE EU-IVDR

NEW! HOLOGRAFT ONE

Omixon Blog

Werfen acquires Omixon

16/10/2024
Barcelona, Spain May 15, 2024.- Werfen announced today that it has agreed to acquire Omixon, a privately held corporation...

more

SEE MORE »

Events

EVENTS 2024

SEE MORE »

FOLLOW US

TESTIMONIALS

Testimonials

  • The NanoTYPE HLA typing assay is optimally designed and supported by a clear protocol so that the workflow can be easily integrated into any H&I laboratory to be used in daily routine. Dr.Monica Dutescu, MD, PhD, National HLA Laboratory, National Blood Transfusion Institute "Prof.Dr. C.T. Nicolau"
  • “Once again, I congratulate the new version 4.2 of the Twin which is much faster and optimized in processing time and alignment." Romulo Vianna, PhD Rio de Janeiro, State University |UERJ
  • "It's astonishing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
  • “We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single-end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
  • "The Holotype HLA method is optimally designed for the service laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company that works with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
  • “Omixon has developed an excellent direct genotyping method from next-generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
  • “NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy-to-use analytical methods and software tools that aid the generation of accurate results are critical for the success of this groundbreaking new technology.”Dr. Lajos Pusztai, Professor at the University of Texas MD
    Anderson Cancer Center
  • “Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek
  • "Omixon's Holotype HLA provided greater accuracy with fewer ambiguities, particularly for problematic specimens, than our Sanger SBT procedures."Dr. Pamela Kimball, VCU Health System Authority
  • "The NGS kit for HLA genotyping, unlike others available in the market, provides complete control of the reactions from the beginning to the end of the technical process, thus providing a higher cost-benefit ratio for the Laboratory. HLA TWIN is the best and most complete HLA genotyping program on the market and has helped us solve many problems in our laboratory routine."Dr. Rafael Cita, Fundação Pio XII Barretos
  • "Due to the higher throughput and resolution compared to Sanger sequencing, NGS technology improved significantly HLA typing. Omixon`s Holotype HLA workflow and HLA Twin software could be easily implemented in H&I laboratories. Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT but also in organ transplantation."Dr. Milena Ivanova, Bulgarian Bone Marrow Registry

 

Omixon Academy

Improve your knowledge!

Our Training Series provide ABHI accredited webinars, workshops, onsite trainings and online demo.

Read more

 

 

Contact Us

Just ask! Get answers!

Your questions and comments are important to us. We’ve got you covered.

Read more

 

 

Omixon Newsletter

Subscribe now!

By clicking 'Ok' I accept the
Privacy Policy

 

Sitemap

Products

  • NanoTYPE™
  • Holotype HLA™
  • HLA Twin™
  • HoloGRAFT™
  • Training and Field Support

 

Company

  • About
  • Board of Directors
  • Scientific Advisory Board
  • CSR Activities
  • Careers / Internships
  • MyOmixon
  • Cooperations and Sponsorships
  • Events

 

Omixon Academy

  • HLA Twin Videos
  • Lab Train Me Videos
  • Posters
  • Workshops
  • Symposiums
  • Webinars
  • Accreditation

 

Contact us

  • Distributors and Agents

Our Mailing Address:

Omixon Biocomputing Ltd.
H-1117 Budapest,
Kaposvár u. 14-18.,
Hungary, EU

US Branch Office:

Omixon Inc.
6 Liberty Square # 2823
Boston, MA 02109
United States

sales@omixon.com | www.omixon.com

support@omixon.com

 

2012-2022, Omixon Inc. All Rights Reserved.